Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F B Wright

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Plos One|February 18, 2021
Metformin doses to ensure efficacy and safety in patients with reduced kidney functionIsabelle H S Kuan, Luke C Wilson, Jed C Leishman, et al.
British Journal of Clinical Pharmacology|May 18, 2021
Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?Sudeep Pradhan, Stephen B Duffull, Luke C Wilson, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|May 14, 2024
The experiences and perspectives of people with gout on urate self-monitoringToni J F Michael, Jian S Chan, Stephen Hughes, et al.
Drugs in R&D|May 7, 2014
Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin CPaul K L Chin, Daniel F B Wright, Mei Zhang, et al.
British Journal of Clinical Pharmacology|February 15, 2024
The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools)Daniel F B Wright, Hailemichael Z Hishe, Sophie L Stocker, et al.
Joint Bone Spine|August 13, 2013
Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromaroneRebecca L Roberts, Mary C Wallace, Daniel F B Wright, et al.
British Journal of Clinical Pharmacology|April 19, 2017
Individualising the dose of allopurinol in patients with goutDiluk R W Kannangara, Garry G Graham, Daniel F B Wright, et al.
Annual Review of Pharmacology and Toxicology|October 9, 2020
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug TherapyAdam S Darwich, Thomas M Polasek, Jeffrey K Aronson, et al.
Intensive Care Medicine|August 13, 2025
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyJason A Roberts, Marta Ulldemolins, Xin Liu, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Plos One|February 18, 2021
Metformin doses to ensure efficacy and safety in patients with reduced kidney functionIsabelle H S Kuan, Luke C Wilson, Jed C Leishman, et al.
British Journal of Clinical Pharmacology|May 18, 2021
Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?Sudeep Pradhan, Stephen B Duffull, Luke C Wilson, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|May 14, 2024
The experiences and perspectives of people with gout on urate self-monitoringToni J F Michael, Jian S Chan, Stephen Hughes, et al.
Drugs in R&D|May 7, 2014
Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin CPaul K L Chin, Daniel F B Wright, Mei Zhang, et al.
British Journal of Clinical Pharmacology|February 15, 2024
The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools)Daniel F B Wright, Hailemichael Z Hishe, Sophie L Stocker, et al.
Joint Bone Spine|August 13, 2013
Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromaroneRebecca L Roberts, Mary C Wallace, Daniel F B Wright, et al.
British Journal of Clinical Pharmacology|April 19, 2017
Individualising the dose of allopurinol in patients with goutDiluk R W Kannangara, Garry G Graham, Daniel F B Wright, et al.
Annual Review of Pharmacology and Toxicology|October 9, 2020
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug TherapyAdam S Darwich, Thomas M Polasek, Jeffrey K Aronson, et al.
Intensive Care Medicine|August 13, 2025
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyJason A Roberts, Marta Ulldemolins, Xin Liu, et al.
Pageof 8